首页> Japanese journal of clinical oncology> Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study.

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study.

导出 OA

翻译打印收藏纠错

第一作者： Seiichiro,Ozono

第一单位： Department of Urology, Hamamatsu University School of Medicine, Shizuoka.

作者： Seiichiro,Ozono ^[1] ; Taiji,Tsukamoto ^[2] ; Seiji,Naito ^[3] ; Yasuo,Ohashi ^[4] ; Takeshi,Ueda ^[5] ; Tsutomu,Nishiyama ^[6] ; Hideki,Maeda ^[7] ; Hidehito,Kusuoka ^[8] ; Rio,Akazawa ^[9] ; Mototsugu,Ito ^[10] ; Hideyuki,Akaza ^[11]

作者单位： Department of Urology, Hamamatsu University School of Medicine, Shizuoka. ^[1] Department of Urology, Sapporo Medical University, Hokkaido. ^[2] Department of Urology, Harasanshin Hospital, Fukuoka. ^[3] Department of Integrated Science and Engineering for Sustainable Society, Chuo University, Tokyo. ^[4] Prostate Center and Division of Urology, Chiba Cancer Center, Chiba. ^[5] Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata. ^[6] Medical Research, Medical Affairs, Astellas Pharma Inc., Tokyo. ^[7] Japan-Asia Clinical Development 1, Development, Astellas Pharma Inc., Tokyo. ^[8] Japan-Asia Data Science, Development, Astellas Pharma Inc., Tokyo. ^[9] Japan-Asia Clinical Pharmacology, Development, Astellas Pharma Inc., Tokyo. ^[10] Strategic Investigation on Comprehensive Cancer Network, The University of Tokyo, Tokyo, Japan. ^[11]

关键词 Japan clinical trial degarelix gonadotropin-releasing hormone antagonist prostate cancer